Barclays Maintains an 'Overweight' on Merck (MRK); Model Update: Termination of Animal Health JV
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Merck (NYSE: MRK), PT $41.
Barclays analyst says, "This morning (3.22), Merck and Sanofi-aventis (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "This morning (3.22), Merck and Sanofi-aventis (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
